{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:27:44Z","timestamp":1793071664673,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Islamic Azad University, Babol Branch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00894-022-05286-6","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T01:02:21Z","timestamp":1661734941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Natural inhibitors of SARS-CoV-2 main protease: structure based pharmacophore modeling, molecular docking and molecular dynamic simulation studies"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-2533","authenticated-orcid":false,"given":"Mohammad","family":"Halimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvindokht","family":"Bararpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"5286_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eap.2020.08.002","volume":"68","author":"CA Tisdell","year":"2020","unstructured":"Tisdell CA (2020) Economic, social and political issues raised by the COVID-19 pandemic. Econ Anal Policy 68:17\u201328","journal-title":"Econ Anal Policy"},{"key":"5286_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3110","volume":"370","author":"JH Tanne","year":"2020","unstructured":"Tanne JH (2020) Covid-19: Mental health and economic problems are worse in US than in other rich nations. BMJ 370:m3110","journal-title":"BMJ"},{"issue":"10","key":"5286_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240876","volume":"15","author":"C Codagnone","year":"2020","unstructured":"Codagnone C et al (2020) Assessing concerns for the economic consequence of the COVID-19 response and mental health problems associated with economic vulnerability and negative economic shock in Italy, Spain, and the United Kingdom. PLoS ONE 15(10):e0240876","journal-title":"PLoS ONE"},{"key":"5286_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","volume":"114","author":"C Zheng","year":"2022","unstructured":"Zheng C et al (2022) Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 114:252\u2013260","journal-title":"Int J Infect Dis"},{"issue":"4","key":"5286_CR5","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S1473-3099(20)30923-3","volume":"21","author":"JA Singh","year":"2021","unstructured":"Singh JA, Upshur REG (2021) The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. Lancet Infect Dis 21(4):e103\u2013e109","journal-title":"Lancet Infect Dis"},{"key":"5286_CR6","doi-asserted-by":"crossref","unstructured":"Samaranayake LP, Seneviratne CJ, Fakhruddin KS (2021) Coronavirus disease 2019 (COVID-19) vaccines: a concise review. Oral Dis 00:1\u201311","DOI":"10.1111\/odi.13916"},{"issue":"1","key":"5286_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11655-021-3313-x","volume":"28","author":"K Shi","year":"2022","unstructured":"Shi K et al (2022) Severe type of COVID-19: pathogenesis, warning indicators and treatment. Chin J Integr Med 28(1):3\u201311","journal-title":"Chin J Integr Med"},{"issue":"4","key":"5286_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/jmv.27512","volume":"94","author":"Q Cheng","year":"2021","unstructured":"Cheng Q et al (2021) Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: a network meta-analysis of randomized controlled trials. J Med Virol 94(4):1617\u20131626","journal-title":"J Med Virol"},{"issue":"3","key":"5286_CR9","first-page":"311","volume":"104","author":"S Odeti","year":"2021","unstructured":"Odeti S, Yellepeddi VK (2021) Remdesivir (Veklury) for the treatment of COVID-19 in hospitalized patients. Am Fam Physician 104(3):311\u2013312","journal-title":"Am Fam Physician"},{"issue":"1","key":"5286_CR10","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1093\/cid\/ciab875","volume":"75","author":"E Mozaffari","year":"2021","unstructured":"Mozaffari E et al (2021) Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 75(1):e450\u2013e458","journal-title":"Clin Infect Dis"},{"key":"5286_CR11","unstructured":"No authors listed (2022) COVID-19 update: baricitinib (Olumiant) FDA-approved for treatment of COVID-19. Med Lett Drugs Ther 64(1652):e2\u2013e3"},{"key":"5286_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1695","volume":"378","author":"JH Tanne","year":"2022","unstructured":"Tanne JH (2022) Covid-19: FDA authorises pharmacists to prescribe Paxlovid. BMJ 378:o1695","journal-title":"BMJ"},{"issue":"5","key":"5286_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jmii.2021.05.009","volume":"54","author":"E Perez-Alba","year":"2021","unstructured":"Perez-Alba E et al (2021) Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: a retrospective analysis. J Microbiol Immunol Infect 54(5):787\u2013793","journal-title":"J Microbiol Immunol Infect"},{"key":"5286_CR14","unstructured":"No authors listed (2022) Paxlovid for treatment of COVID-19. Med Lett Drugs Ther 64(1642):9\u201310"},{"key":"5286_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2713","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase E (2021) Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 375:n2713","journal-title":"BMJ"},{"key":"5286_CR16","doi-asserted-by":"crossref","unstructured":"Sharma A, Gupta SP (2017) Fundamentals of viruses and their proteases. Viral Proteases Their Inhib 1\u201324","DOI":"10.1016\/B978-0-12-809712-0.00001-0"},{"issue":"4","key":"5286_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/med.21475","volume":"38","author":"AA Agbowuro","year":"2018","unstructured":"Agbowuro AA et al (2018) Proteases and protease inhibitors in infectious diseases. Med Res Rev 38(4):1295\u20131331","journal-title":"Med Res Rev"},{"issue":"12","key":"5286_CR18","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.3390\/microorganisms9122481","volume":"9","author":"R Razali","year":"2021","unstructured":"Razali R, Asis H, Budiman C (2021) Structure-function characteristics of SARS-CoV-2 proteases and their potential inhibitors from microbial sources. Microorganisms 9(12):2481","journal-title":"Microorganisms"},{"key":"5286_CR19","first-page":"4","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science 368:4","journal-title":"Science"},{"issue":"7811","key":"5286_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7811):289\u2013293","journal-title":"Nature"},{"key":"5286_CR21","first-page":"8325467","volume":"2016","author":"F Klein","year":"2016","unstructured":"Klein F et al (2016) Two-year follow-up analysis of telaprevir-based antiviral triple therapy for HCV recurrence in genotype 1 infected liver graft recipients as a first step towards modern HCV therapy. Hepat Res Treat 2016:8325467","journal-title":"Hepat Res Treat"},{"issue":"25","key":"5286_CR22","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405\u20132416","journal-title":"N Engl J Med"},{"issue":"9","key":"5286_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2174\/092986709787581789","volume":"16","author":"I Gentile","year":"2009","unstructured":"Gentile I et al (2009) Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 16(9):1115\u20131121","journal-title":"Curr Med Chem"},{"issue":"12","key":"5286_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","volume":"28","author":"DW Kneller","year":"2020","unstructured":"Kneller DW et al (2020) Malleability of the SARS-CoV-2 3CL M(pro) active-site cavity facilitates binding of clinical antivirals. Structure 28(12):1313-1320 e3","journal-title":"Structure"},{"issue":"8","key":"5286_CR25","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1021\/acs.jmedchem.1c00058","volume":"64","author":"DW Kneller","year":"2021","unstructured":"Kneller DW et al (2021) Direct observation of protonation state modulation in SARS-CoV-2 main protease upon inhibitor binding with neutron crystallography. J Med Chem 64(8):4991\u20135000","journal-title":"J Med Chem"},{"issue":"6536","key":"5286_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"J Qiao","year":"2021","unstructured":"Qiao J et al (2021) SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model. Science 371(6536):1374\u20131378","journal-title":"Science"},{"issue":"3","key":"5286_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1039\/D0MD00367K","volume":"12","author":"R Oerlemans","year":"2020","unstructured":"Oerlemans R et al (2020) Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics. RSC Med Chem 12(3):370\u2013379","journal-title":"RSC Med Chem"},{"key":"5286_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.723233","volume":"12","author":"D Stan","year":"2021","unstructured":"Stan D et al (2021) Natural compounds with antimicrobial and antiviral effect and nanocarriers used for their transportation. Front Pharmacol 12:723233","journal-title":"Front Pharmacol"},{"issue":"33","key":"5286_CR29","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.2174\/1381612826666201118111151","volume":"27","author":"YS Wijayasinghe","year":"2021","unstructured":"Wijayasinghe YS et al (2021) Natural products: a rich source of antiviral drug lead candidates for the management of COVID-19. Curr Pharm Des 27(33):3526\u20133550","journal-title":"Curr Pharm Des"},{"issue":"W1","key":"5286_CR30","doi-asserted-by":"publisher","first-page":"W442","DOI":"10.1093\/nar\/gkw287","volume":"44","author":"J Sunseri","year":"2016","unstructured":"Sunseri J, Koes DR (2016) Pharmit: interactive exploration of chemical space. Nucleic Acids Res 44(W1):W442\u2013W448","journal-title":"Nucleic Acids Res"},{"key":"5286_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymeth.2014.10.013","volume":"71","author":"A Vuorinen","year":"2015","unstructured":"Vuorinen A, Schuster D (2015) Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. Methods 71:113\u2013134","journal-title":"Methods"},{"key":"5286_CR32","doi-asserted-by":"crossref","unstructured":"Grosdidier A, Zoete V, Michielin O (2011) SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39(Web Server issue): W270\u20137","DOI":"10.1093\/nar\/gkr366"},{"issue":"10","key":"5286_CR33","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/jcc.21797","volume":"32","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier A, Zoete V, Michielin O (2011) Fast docking using the CHARMM force field with EADock DSS. J Comput Chem 32(10):2149\u20132159","journal-title":"J Comput Chem"},{"issue":"14","key":"5286_CR34","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger MM et al (2012) Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 55(14):6582\u20136594","journal-title":"J Med Chem"},{"issue":"9","key":"5286_CR35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/1568026611313090010","volume":"13","author":"RC Braga","year":"2013","unstructured":"Braga RC, Andrade CH (2013) Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? Curr Top Med Chem 13(9):1127\u20131138","journal-title":"Curr Top Med Chem"},{"key":"5286_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1423-0127-18-8","volume":"18","author":"SH Lu","year":"2011","unstructured":"Lu SH et al (2011) The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci 18:8","journal-title":"J Biomed Sci"},{"key":"5286_CR37","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717","journal-title":"Sci Rep"},{"issue":"1\u20133","key":"5286_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA et al (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1\u20133):3\u201325","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"5286_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","volume":"24","author":"LLG Ferreira","year":"2019","unstructured":"Ferreira LLG, Andricopulo AD (2019) ADMET modeling approaches in drug discovery. Drug Discov Today 24(5):1157\u20131165","journal-title":"Drug Discov Today"},{"issue":"W1","key":"5286_CR40","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee P et al (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46(W1):W257\u2013W263","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5286_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell MD et al (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 4(1):17","journal-title":"J Cheminform"},{"issue":"13","key":"5286_CR42","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF et al (2004) UCSF Chimera\u2013a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605\u20131612","journal-title":"J Comput Chem"},{"key":"5286_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ et al (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132:19\u201325","journal-title":"SoftwareX"},{"issue":"11","key":"5286_CR44","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/jcc.21816","volume":"32","author":"V Zoete","year":"2011","unstructured":"Zoete V et al (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32(11):2359\u20132368","journal-title":"J Comput Chem"},{"issue":"9","key":"5286_CR45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"M Karplus","year":"2002","unstructured":"Karplus M, McCammon JA (2002) Molecular dynamics simulations of biomolecules. Nat Struct Biol 9(9):646\u2013652","journal-title":"Nat Struct Biol"},{"issue":"20","key":"5286_CR46","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2174\/1568026618666181025114157","volume":"18","author":"AAT Naqvi","year":"2018","unstructured":"Naqvi AAT et al (2018) Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Curr Top Med Chem 18(20):1755\u20131768","journal-title":"Curr Top Med Chem"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-022-05286-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-022-05286-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-022-05286-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T01:10:33Z","timestamp":1662772233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-022-05286-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5286"],"URL":"https:\/\/doi.org\/10.1007\/s00894-022-05286-6","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"279"}}